莫沙必利

**莫沙必利**
系統（IUPAC）命名名稱
	(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide
臨床數據
Drugs.com	國際藥品名稱
給藥途徑	口服
識別資訊
CAS註冊號	112885-41-3
ATC代碼	None
PubChem	CID 119584
IUPHAR/BPS	242
ChemSpider	106780
UNII	I8MFJ1C0BY
KEGG	D08236
ChEMBL	CHEMBL60889
化學資訊
化學式	C21H25ClFN3O3
摩爾質量	421.893 g/mol
	SMILES Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3; ;
	InChI InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27) ; Key:YPELFRMCRYSPKZ-UHFFFAOYSA-N ;

莫沙必利（英語：Mosapride）是一種消化道促動力藥，選擇性激動 5-HT₄受體，其主要代謝產物M1還具有5HT₃受體的競爭性拮抗作用。^[1]莫沙必利可以加速胃排空，促進全消化道的蠕動，用來治療胃炎、胃食管反流病、功能性消化不良和過敏性腸綜合症。^[2]^[3]^[4]^[5]枸緣酸鹽形式的莫沙必利，由大日本住友製藥在1998年以加斯清為商品名上市銷售。

參見

↑ Tack, J.; Camilleri, M.; Chang, L.; Chey, WD.; Galligan, JJ.; Lacy, BE.; Müller-Lissner, S.; Quigley, EM.; Schuurkes, J. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.. Aliment Pharmacol Ther. Apr 2012, 35 (7): 745–67. PMID 22356640. doi:10.1111/j.1365-2036.2012.05011.x.
↑ Odaka T, Suzuki T, Seza A, Yamaguchi T, Saisho H. [Serotonin 5- HT4 receptor agonist (mosapride citrate)]. Nippon Rinsho. August 2006, 64 (8): 1491–4. PMID 16898619 （日語）.
↑ Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs. 2008, 68 (7): 981–91. PMID 18457463. doi:10.2165/00003495-200868070-00007.
↑ Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.
↑ Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent.Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.